Literature DB >> 8123870

DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

D W Hedley1, G M Clark, C J Cornelisse, D Killander, T Kute, D Merkel.   

Abstract

This is the consensus statement regarding the clinical utility of DNA cytometry in breast cancer from the DNA Cytometry Consensus Conference held in Prout's Neck, Maine, USA, on October 1-4, 1992. Guidelines for clinical DNA cytometry generated at that meeting also appear in this issue of Breast Cancer Research and Treatment.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8123870     DOI： 10.1007/bf00666357

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  43 in total

1.  Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer.

Authors:  H Beerman; V T Smit; P M Kluin; B A Bonsing; J Hermans; C J Cornelisse
Journal:  Cytometry       Date:  1991

2.  One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?

Authors:  M Fernö; B Baldetorp; S B Ewers; I Idvall; H Olsson; H Sigurdsson; D Killander
Journal:  Cytometry       Date:  1992

3.  The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients.

Authors:  J C van der Linden; J Lindeman; J P Baak; C J Meijer; C J Herman
Journal:  Cytometry       Date:  1989-01

4.  DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer.

Authors:  M Eskelinen; P Lipponen; S Papinaho; S Aaltomaa; V M Kosma; P Klemi; K Syrjänen
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

5.  Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer.

Authors:  S M O'Reilly; R S Camplejohn; R R Millis; R D Rubens; M A Richards
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans.

Authors:  G Auer; E Eriksson; E Azavedo; T Caspersson; A Wallgren
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.

Authors:  O P Kallioniemi; T Hietanen; J Mattila; M Lehtinen; K Lauslahti; T Koivula
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

8.  DNA ploidy and survival in breast cancer patients.

Authors:  C J Cornelisse; C J van de Velde; R J Caspers; A J Moolenaar; J Hermans
Journal:  Cytometry       Date:  1987-03

9.  DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication.

Authors:  T E Witzig; N J Gonchoroff; T Therneau; D T Gilbertson; L E Wold; C Grant; J Grande; J A Katzmann; D L Ahmann; J N Ingle
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

10.  Indicators of prognosis in node-negative breast cancer.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245
View more
  3 in total

1.  Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples.

Authors:  J Isola; S DeVries; L Chu; S Ghazvini; F Waldman
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

2.  S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers.

Authors:  H Romero; J Schneider; J Burgos; J Bilbao; F J Rodriguez-Escudero
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  MIB-1 labelling index is an independent prognostic marker in primary breast cancer.

Authors:  R L Jansen; P S Hupperets; J W Arends; S R Joosten-Achjanie; A Volovics; H C Schouten; H F Hillen
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.